On October 30, 2023, Sun Pharmaceutical Industries Limited and Zydus Lifesciences Limited announced that both companies have entered into a licensing agreement to co-market an innovative drug, Desidustat in India.
In September 2023, Sun Pharmaceutical Industries Limited announced that one of its wholly owned subsidiaries has entered into a license agreement with Pharmazz Inc., (Pharmazz), a U.S. based biopharmaceutical company to commercialise a first-in-class innovative drug, Tyvalzi™ (Sovateltide) in India.
In July 2023, on the occasion of National Doctor’s Day, Sun Pharma, India’s largest pharmaceutical company, unveiled an inspiring initiative, titled #SecondBirthDate, to celebrate and honour the incredible contributions made by doctors.
Sun Pharmaceutical Industries Limited announced that one of its wholly owned subsidiaries has launched a novel ophthalmology treatment, CEQUA, in India for patients who have Dry Eye Disease (DED) with inflammation, a commonly occurring condition.
Sun Pharma and Israel-based Moebius Medical Limited recently announced the topline results of their Phase 2b, randomized, double-blind, placebo-controlled, single administration, multiple-dose study evaluating the efficacy and safety of MM-II for the treatment of knee pain in participants with symptomatic knee osteoarthritis.
Sun Pharmaceutical Industries Limited announced the successful completion of its acquisition of Concert Pharmaceuticals, Inc. on March 6, 2023.
India's Sun Pharma acquired US-based Concert for US$ 576 million.
Sun Pharma gross Revenue from operations during FY24 at Rs. 47,758.5 crore (US$ 5.74 billion).
Sun Pharma acquired three brands to boost anti-inflammatory portfolio.
|